I understand what you are trying to point out, however, the drug does not belong to Oncosec. Therefore, they would get more from the use of the Patent by licensing the device alone. As a matter of fact, the latest Patent received by Dhillon this year only secures such device without the inclusion of IL-12. The Patent from Dhillon is for a device that has the correct amount of voltage needed, by maintaining the electric field to about 1300 V/cm without pain or side effects, which is what Oncosec has already proven in their trials.
The following is from September 2012 when Oncosec first received the license to use the electroporation device from University of South Florida.
"OncoSec’s proprietary gene and drug delivery platform, the OncoSec Medical System (OMS) electroporation device, is currently being used to develop the company’s ImmunoPulse and NeoPulse therapies. This platform encompasses patents, technology and other intellectual property for intratumoral methods for delivering drugs and gene-based treatments in humans.
ImmunoPulse involves the application of a brief electric field to the surface of the skin. This temporarily opens pores in the cell membrane, allowing anti-cancer agent DNA IL-12, to be absorbed more efficiently. DNA IL-12, which normally has difficulty penetrating the tumor cell membrane to get inside these cells, has been shown to significantly stimulate the immune system’s T-cells to fight the cancer. The new license from USFRF complements OncoSec’s seminal patents, particularly for the protection of the methods involved in the ImmunoPulse treatment, and specifically for the use of DNA IL-12."
